SV2006002071A - Oxadiazolonas procedimientos para su preparacion y su uso como productos farmaceuticos - Google Patents
Oxadiazolonas procedimientos para su preparacion y su uso como productos farmaceuticosInfo
- Publication number
- SV2006002071A SV2006002071A SV2005002071A SV2005002071A SV2006002071A SV 2006002071 A SV2006002071 A SV 2006002071A SV 2005002071 A SV2005002071 A SV 2005002071A SV 2005002071 A SV2005002071 A SV 2005002071A SV 2006002071 A SV2006002071 A SV 2006002071A
- Authority
- SV
- El Salvador
- Prior art keywords
- disorders
- diseases
- procedures
- preparation
- pharmaceutical products
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 201000010099 disease Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000000841 delta opiate receptor agonist Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008569 process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
OXADIAZOLONAS, PROCEDIMIENTOS PARA SU PREPARACION Y SU USO COMO PRODUCTOS FARMACEUTICOS.LA INVENCION SE REFIERE A OXADIAZOLONAS Y A SUS SALES FISIOLOGICAMENTE ACEPTABLES DERIVADOS FISIOLOGICAMENTE QUE MUESTRAN ACTIVIDAD AGONISTA DE PAR-DELTA. SE DESCRIBEN COMPUESTOS DE FORMULA I (VER FORMULA) EN LA QUE LOS RADICALES SON COMO SE HAN DEFINIDO Y SUS SALES FISIOLOGICAMENTE ACEPTABLES Y PROCEDIMIENTO PARA SU PREPARACIONES. LOS COMPUESTOS SON ADECUADOS PARA EL TRATAMIENTO Y/O PREVENCION DE TRASTORNOS DEL METABOLISMO DE ACIDOS GRASOS Y TRASTORNOS DE USO DE LA GLUCOSA, ASI COMO TRASTORNOS EN LOS QUE ESTA IMPLICADA LA RESISTENCIA A LA INSULINA; ENFERMEDADES NEURIDEGENERATIVAS Y/O TRASTORNOS DE DESMIELINIZACION DE LOS SISTEMAS NERVIOSOS CENTRAL Y PERIFERICO Y/O ENFERMEDADES NEURILOGICAS QUE IMPLICAN PROCESOS NEUROINFLAMATORIOS Y/O ENFERMEDADES NEUROLOGICAS QUE IMPLICAN PROCESOS NEUROINFLAMATORIOS Y/U OTRAS NEUROPATIAS PERIFERICAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04007879A EP1586573B1 (en) | 2004-04-01 | 2004-04-01 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2006002071A true SV2006002071A (es) | 2006-01-30 |
Family
ID=34924545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2005002071A SV2006002071A (es) | 2004-04-01 | 2005-04-01 | Oxadiazolonas procedimientos para su preparacion y su uso como productos farmaceuticos |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US20070179191A1 (es) |
| EP (3) | EP1586573B1 (es) |
| JP (1) | JP2007530612A (es) |
| KR (1) | KR20060135857A (es) |
| CN (1) | CN100582104C (es) |
| AR (1) | AR050576A1 (es) |
| AT (1) | ATE435225T1 (es) |
| AU (1) | AU2005231916A1 (es) |
| BR (1) | BRPI0509517A (es) |
| CA (1) | CA2561627A1 (es) |
| CR (1) | CR8572A (es) |
| CY (1) | CY1109370T1 (es) |
| DE (2) | DE602004004631D1 (es) |
| DK (1) | DK1740583T3 (es) |
| DO (1) | DOP2005000051A (es) |
| EC (1) | ECSP066892A (es) |
| ES (1) | ES2329484T3 (es) |
| GT (1) | GT200500028A (es) |
| HR (1) | HRP20090493T1 (es) |
| IL (1) | IL178056A0 (es) |
| MA (1) | MA28495B1 (es) |
| MY (1) | MY142431A (es) |
| NO (1) | NO20064981L (es) |
| PA (1) | PA8628701A1 (es) |
| PE (1) | PE20060323A1 (es) |
| PL (1) | PL1740583T3 (es) |
| PT (1) | PT1740583E (es) |
| RS (1) | RS51186B (es) |
| RU (1) | RU2374243C2 (es) |
| SI (1) | SI1740583T1 (es) |
| SV (1) | SV2006002071A (es) |
| TN (1) | TNSN06317A1 (es) |
| TW (1) | TW200602342A (es) |
| UA (1) | UA84203C2 (es) |
| UY (1) | UY28837A1 (es) |
| WO (1) | WO2005097786A1 (es) |
| ZA (1) | ZA200606870B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
| BRPI0616477A2 (pt) | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de 2-amintiazóis e 2-amino-oxazóis, processos para a sua preparação e seus usos |
| WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| CN101273036A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途 |
| KR20090066289A (ko) | 2006-09-08 | 2009-06-23 | 로드아일랜드하스피틀 | 알코올 유발성 뇌 질환의 치료, 예방 및 역행 |
| AU2007292874B2 (en) | 2006-09-08 | 2013-11-21 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| AU2009256982A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| EP2288607B1 (en) | 2008-06-09 | 2014-09-24 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| WO2009149819A1 (en) * | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| EP2349285B1 (en) | 2008-10-10 | 2016-03-23 | Dara Biosciences, Inc. | Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain |
| EP3135672B9 (en) * | 2008-10-10 | 2020-05-20 | VM Discovery, Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| ES2439801T3 (es) * | 2009-08-05 | 2014-01-24 | Daiichi Sankyo Company, Limited | Derivado de sulfona |
| EP2463279B1 (en) * | 2009-08-05 | 2014-02-12 | Daiichi Sankyo Company, Limited | 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity |
| WO2015061481A1 (en) | 2013-10-23 | 2015-04-30 | Dara Biosciences, Inc. | Methods of treating liquid tumors using compositions comprising spicamycin derivatives |
| US20220387393A1 (en) * | 2019-11-06 | 2022-12-08 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256680A (en) | 1988-11-29 | 1993-10-26 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents |
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| TW222626B (es) * | 1991-07-22 | 1994-04-21 | Pfizer | |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| CA2241567A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| UA72181C2 (uk) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| RU2200161C2 (ru) | 1996-12-31 | 2003-03-10 | Др. Редди'З Рисерч Фаундейшн | Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| IL133604A0 (en) | 1997-07-16 | 2001-04-30 | Novo Nordisk As | Fused 1, 2, 4-thiadiazine derivatives, their preparation and use |
| CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
| DE60027420T2 (de) | 1999-04-28 | 2006-11-16 | Aventis Pharma Deutschland Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| AU773505B2 (en) | 1999-06-18 | 2004-05-27 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| JP2003504082A (ja) | 1999-07-09 | 2003-02-04 | コヘージョン テクノロジーズ， インコーポレイテッド | エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法 |
| ATE245636T1 (de) | 1999-07-29 | 2003-08-15 | Lilly Co Eli | Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten |
| KR20020033778A (ko) | 1999-09-01 | 2002-05-07 | 로버트 흐라이탁, 미쉘 베스트 | 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도 |
| TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| PT1237855E (pt) | 1999-12-03 | 2004-06-30 | Astrazeneca Ab | Forma cristalina do acido (s)-2-etoxi-3-¬4-(2-{4-metanosulfoniloxifenil}etoxi)fenil|propanoico |
| SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
| CA2400226C (en) | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| YU80302A (sh) | 2000-04-25 | 2005-11-28 | Kyorin Pharmaceutical Co. Ltd. | Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog |
| PT1277736E (pt) | 2000-04-28 | 2007-10-12 | Asahi Kasei Pharma Corp | Novos compostos bicíclicos |
| ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| TR200401029T4 (tr) | 2000-06-09 | 2004-06-21 | Aventis Pharma Deutschland Gmbh | Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| KR100833089B1 (ko) | 2000-12-21 | 2008-05-29 | 사노피-아벤티스 도이칠란트 게엠베하 | 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물 |
| EP1368011A1 (en) | 2001-02-22 | 2003-12-10 | SmithKline Beecham Corporation | Method for treating ppar gamma mediated diseases |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| PT1425014E (pt) | 2001-08-31 | 2007-03-30 | Sanofi Aventis Deutschland | Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar |
| AU2002347985A1 (en) * | 2001-11-15 | 2003-06-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| EP1615900A1 (en) | 2003-04-01 | 2006-01-18 | Eli Lilly And Company | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors |
| EP1613608A1 (en) | 2003-04-01 | 2006-01-11 | Eli Lilly And Company | Phospholipase inhibitors |
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| CN101273036A (zh) * | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途 |
-
2004
- 2004-04-01 DE DE602004004631T patent/DE602004004631D1/de not_active Expired - Lifetime
- 2004-04-01 EP EP04007879A patent/EP1586573B1/en not_active Expired - Lifetime
-
2005
- 2005-02-17 GT GT200500028A patent/GT200500028A/es unknown
- 2005-03-19 PT PT05716233T patent/PT1740583E/pt unknown
- 2005-03-19 RS RSP-2009/0391A patent/RS51186B/sr unknown
- 2005-03-19 HR HR20090493T patent/HRP20090493T1/xx unknown
- 2005-03-19 AU AU2005231916A patent/AU2005231916A1/en not_active Abandoned
- 2005-03-19 EP EP09005458A patent/EP2083006A1/en not_active Withdrawn
- 2005-03-19 RU RU2006138498/04A patent/RU2374243C2/ru not_active IP Right Cessation
- 2005-03-19 CN CN200580010743A patent/CN100582104C/zh not_active Expired - Fee Related
- 2005-03-19 DK DK05716233T patent/DK1740583T3/da active
- 2005-03-19 ES ES05716233T patent/ES2329484T3/es not_active Expired - Lifetime
- 2005-03-19 EP EP05716233A patent/EP1740583B1/en not_active Expired - Lifetime
- 2005-03-19 BR BRPI0509517-4A patent/BRPI0509517A/pt not_active IP Right Cessation
- 2005-03-19 JP JP2007505433A patent/JP2007530612A/ja not_active Abandoned
- 2005-03-19 UA UAA200611486A patent/UA84203C2/ru unknown
- 2005-03-19 PL PL05716233T patent/PL1740583T3/pl unknown
- 2005-03-19 AT AT05716233T patent/ATE435225T1/de not_active IP Right Cessation
- 2005-03-19 DE DE602005015204T patent/DE602005015204D1/de not_active Expired - Lifetime
- 2005-03-19 CA CA002561627A patent/CA2561627A1/en not_active Abandoned
- 2005-03-19 WO PCT/EP2005/002950 patent/WO2005097786A1/en not_active Ceased
- 2005-03-19 SI SI200530778T patent/SI1740583T1/sl unknown
- 2005-03-19 KR KR1020067020503A patent/KR20060135857A/ko not_active Ceased
- 2005-03-22 PE PE2005000323A patent/PE20060323A1/es not_active Application Discontinuation
- 2005-03-30 TW TW094109908A patent/TW200602342A/zh unknown
- 2005-03-30 DO DO2005000051A patent/DOP2005000051A/es unknown
- 2005-03-30 AR ARP050101221A patent/AR050576A1/es not_active Application Discontinuation
- 2005-03-31 MY MYPI20051461A patent/MY142431A/en unknown
- 2005-04-01 SV SV2005002071A patent/SV2006002071A/es not_active Application Discontinuation
- 2005-04-01 PA PA20058628701A patent/PA8628701A1/es unknown
- 2005-04-01 UY UY28837A patent/UY28837A1/es unknown
-
2006
- 2006-08-15 ZA ZA200606870A patent/ZA200606870B/en unknown
- 2006-08-24 CR CR8572A patent/CR8572A/es not_active Application Discontinuation
- 2006-09-13 IL IL178056A patent/IL178056A0/en unknown
- 2006-09-26 US US11/535,266 patent/US20070179191A1/en not_active Abandoned
- 2006-09-29 MA MA29354A patent/MA28495B1/fr unknown
- 2006-09-29 EC EC2006006892A patent/ECSP066892A/es unknown
- 2006-09-29 TN TNP2006000317A patent/TNSN06317A1/en unknown
- 2006-10-31 NO NO20064981A patent/NO20064981L/no not_active Application Discontinuation
-
2008
- 2008-06-05 US US12/133,405 patent/US7709509B2/en not_active Expired - Fee Related
- 2008-06-05 US US12/133,408 patent/US20080262052A1/en not_active Abandoned
-
2009
- 2009-09-16 CY CY20091100958T patent/CY1109370T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2006002071A (es) | Oxadiazolonas procedimientos para su preparacion y su uso como productos farmaceuticos | |
| SV2009003293A (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimiento para su preparacion y su uso como agentes farmaceuticos | |
| DOP2006000205A (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
| UY31609A1 (es) | "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026." | |
| CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
| CO2022000659A2 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| CU20110221A7 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| CL2012003171A1 (es) | Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias. | |
| UY31873A (es) | Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| PA8596801A1 (es) | Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos | |
| CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| Sasaki et al. | A mouse model of peripheral postischemic dysesthesia: involvement of reperfusion-induced oxidative stress and TRPA1 channel | |
| UY31874A (es) | Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| UY29065A1 (es) | Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos. | |
| SV2006002135A (es) | Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos | |
| PA8596701A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos | |
| UY29848A1 (es) | (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos | |
| PA8596601A1 (es) | Derivados cicloalquilo que tienen grupos acido carboxilico bioisostericos, procesos para su preparacion y su uso como composiciones farmaceuticas | |
| UY29849A1 (es) | 4-oxi-n-(1.3.4)-tiadiazol-2-il-bencenosulfonamidas, procesos para su preparación y su uso como productos farmacéuticos. | |
| GT200600435A (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos. | |
| PA8641601A1 (es) | Derivados del acido acetico con sustituyentes ciclohexilmetoxi, procedimiento para su preparacion y su uso como medicamentos | |
| DOP2009000128A (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant | ||
| FD | Lapse |